BioSpace News Archive

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, dry eye, retinal diseases and other diseases of the eye today announced the appointment of Michelle Senchyna, Ph.D., as Vice President,

Terrace Global Inc. (“Terrace Global” or the “Company”) (TSXV:TRCE) is pleased to announce that effective immediately, Stephen Lermer has joined the Company as President and Chief Operating Officer.

Allergan plc (NYSE: AGN) announced today its Be The Difference philanthropic program supporting children and their families who may benefit from treatment with BOTOX® (onabotulinumtoxinA) for pediatric upper limb spasticity.

Catalent, Inc. (NYSE: CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced financial results for the second quarter of fiscal year 2020, which ended December 31, 2019, as well as its agreement to acquire MaSTherCell Global, Inc., a leading cell therapy development and manufacturing provider with facilities in Belgium and Texas

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”), a producer of high-grade cannabis extracted ingredients for the pharmaceutical, nutraceutical, therapeutical and cosmetic industries, is pleased to announce it has appointed Prf. Dr. Eurico Castro Alves as a new member of its Advisory Board.

COCRYSTAL PHARMA, INC. (NASDAQ: COCP) (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel antiviral therapeutics, today announced the closing of its registered direct offering with two institutional investors for 3,492,063 shares of common stock.

VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, announced today that Prof. Dror Harats, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference,

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it received notice from The Nasdaq Stock Market LLC (“NASDAQ”) on January 31, 2020 indicating that the Company has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule

New data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA® (apalutamide), niraparib and BALVERSA™ (erdafitinib)

Organizations Launch Social Media Campaign and Offer SightMatters.com to Provide People with AMD and Caregivers with Educational Information, AMD Action Plan and More